Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma

A multiinstitutional study in Japan

Daisuke Kawakita, Yuichiro Tada, Yorihisa Imanishi, Shintaro Beppu, Kiyoaki Tsukahara, Satoshi Kano, Hiroyuki Ozawa, Kenji Okami, Yuichiro Sato, Akira Shimizu, Yukiko Sato, Chihiro Fushimi, Soichiro Takase, Takuro Okada, Hiroki Sato, Kuninori Otsuka, Yoshihiro Watanabe, Akihiro Sakai, Koji Ebisumoto, Takafumi Togashi & 6 others Yushi Ueki, Hisayuki Ota, Tomotaka Shimura, Toyoyuki Hanazawa, Shingo Murakami, Toshitaka Nagao

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophilto- lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models. High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value < 0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value < 0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.

Original languageEnglish
Pages (from-to)1083-1091
Number of pages9
JournalOncotarget
Volume8
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Salivary Ducts
Japan
Biomarkers
Carcinoma
Survival
Lymphocytes
Disease-Free Survival
C-Reactive Protein
Blood Platelets
Multivariate Analysis
Proportional Hazards Models
Cohort Studies
Retrospective Studies
Confidence Intervals

Keywords

  • CRP
  • MGPS
  • NLR
  • Salivary duct carcinoma
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma : A multiinstitutional study in Japan. / Kawakita, Daisuke; Tada, Yuichiro; Imanishi, Yorihisa; Beppu, Shintaro; Tsukahara, Kiyoaki; Kano, Satoshi; Ozawa, Hiroyuki; Okami, Kenji; Sato, Yuichiro; Shimizu, Akira; Sato, Yukiko; Fushimi, Chihiro; Takase, Soichiro; Okada, Takuro; Sato, Hiroki; Otsuka, Kuninori; Watanabe, Yoshihiro; Sakai, Akihiro; Ebisumoto, Koji; Togashi, Takafumi; Ueki, Yushi; Ota, Hisayuki; Shimura, Tomotaka; Hanazawa, Toyoyuki; Murakami, Shingo; Nagao, Toshitaka.

In: Oncotarget, Vol. 8, No. 1, 2017, p. 1083-1091.

Research output: Contribution to journalArticle

Kawakita, D, Tada, Y, Imanishi, Y, Beppu, S, Tsukahara, K, Kano, S, Ozawa, H, Okami, K, Sato, Y, Shimizu, A, Sato, Y, Fushimi, C, Takase, S, Okada, T, Sato, H, Otsuka, K, Watanabe, Y, Sakai, A, Ebisumoto, K, Togashi, T, Ueki, Y, Ota, H, Shimura, T, Hanazawa, T, Murakami, S & Nagao, T 2017, 'Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: A multiinstitutional study in Japan', Oncotarget, vol. 8, no. 1, pp. 1083-1091. https://doi.org/10.18632/oncotarget.13565
Kawakita, Daisuke ; Tada, Yuichiro ; Imanishi, Yorihisa ; Beppu, Shintaro ; Tsukahara, Kiyoaki ; Kano, Satoshi ; Ozawa, Hiroyuki ; Okami, Kenji ; Sato, Yuichiro ; Shimizu, Akira ; Sato, Yukiko ; Fushimi, Chihiro ; Takase, Soichiro ; Okada, Takuro ; Sato, Hiroki ; Otsuka, Kuninori ; Watanabe, Yoshihiro ; Sakai, Akihiro ; Ebisumoto, Koji ; Togashi, Takafumi ; Ueki, Yushi ; Ota, Hisayuki ; Shimura, Tomotaka ; Hanazawa, Toyoyuki ; Murakami, Shingo ; Nagao, Toshitaka. / Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma : A multiinstitutional study in Japan. In: Oncotarget. 2017 ; Vol. 8, No. 1. pp. 1083-1091.
@article{4ae213abb2464a71a40021728c503a9f,
title = "Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: A multiinstitutional study in Japan",
abstract = "The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophilto- lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models. High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7{\%} vs 66.1{\%}, p-value=0.003; 3-year progression-free survival (PFS): 0.0{\%} vs 27.9{\%}, p-value < 0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1{\%} vs 68.2{\%}, p-value=0.001; 3-year PFS: 7.1{\%} vs 31.1{\%}, p-value < 0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95{\%} confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.",
keywords = "CRP, MGPS, NLR, Salivary duct carcinoma, Survival",
author = "Daisuke Kawakita and Yuichiro Tada and Yorihisa Imanishi and Shintaro Beppu and Kiyoaki Tsukahara and Satoshi Kano and Hiroyuki Ozawa and Kenji Okami and Yuichiro Sato and Akira Shimizu and Yukiko Sato and Chihiro Fushimi and Soichiro Takase and Takuro Okada and Hiroki Sato and Kuninori Otsuka and Yoshihiro Watanabe and Akihiro Sakai and Koji Ebisumoto and Takafumi Togashi and Yushi Ueki and Hisayuki Ota and Tomotaka Shimura and Toyoyuki Hanazawa and Shingo Murakami and Toshitaka Nagao",
year = "2017",
doi = "10.18632/oncotarget.13565",
language = "English",
volume = "8",
pages = "1083--1091",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",

}

TY - JOUR

T1 - Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma

T2 - A multiinstitutional study in Japan

AU - Kawakita, Daisuke

AU - Tada, Yuichiro

AU - Imanishi, Yorihisa

AU - Beppu, Shintaro

AU - Tsukahara, Kiyoaki

AU - Kano, Satoshi

AU - Ozawa, Hiroyuki

AU - Okami, Kenji

AU - Sato, Yuichiro

AU - Shimizu, Akira

AU - Sato, Yukiko

AU - Fushimi, Chihiro

AU - Takase, Soichiro

AU - Okada, Takuro

AU - Sato, Hiroki

AU - Otsuka, Kuninori

AU - Watanabe, Yoshihiro

AU - Sakai, Akihiro

AU - Ebisumoto, Koji

AU - Togashi, Takafumi

AU - Ueki, Yushi

AU - Ota, Hisayuki

AU - Shimura, Tomotaka

AU - Hanazawa, Toyoyuki

AU - Murakami, Shingo

AU - Nagao, Toshitaka

PY - 2017

Y1 - 2017

N2 - The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophilto- lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models. High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value < 0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value < 0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.

AB - The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophilto- lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models. High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value < 0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value < 0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.

KW - CRP

KW - MGPS

KW - NLR

KW - Salivary duct carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85009727622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009727622&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13565

DO - 10.18632/oncotarget.13565

M3 - Article

VL - 8

SP - 1083

EP - 1091

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -